$GLTO News

Last published 8mo ago

8mo agoGLTOGalecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood DisordersGlobeNewswire-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in
8mo agoGLTOGalecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2,
8mo agoGLTOGalecto to Participate in Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswireBOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate
9mo agoGLTOGalecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 MillionGlobeNewswireBOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today
9mo agoGLTOGalecto Announces Pricing of $275 Million Underwritten Public OfferingGlobeNewswireBOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today
9mo agoGLTOGalecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockGlobeNewswireBOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today
10mo agoGLTOGalecto Highlights Key Strategic Priorities and Anticipated 2026 MilestonesGlobeNewswireDMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous
11mo agoGLTOGalecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the "Company" or "Galecto") (NASDAQ:GLTO) today announced that the Company's Board of Directors approved the grant of non-qualified stock options to purchase
1y agoGLTOGalecto Announces Acquisition of Damora TherapeuticsGlobeNewswireAcquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms
1y agoGLTOGalecto Reports Third Quarter 2025 Operating and Financial ResultsGlobeNewswireBOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its
1y agoGLTOGalecto to Highlight GB3226 Program at ASH 2025GlobeNewswireTwo Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) BOSTON, Nov. 03, 2025
1y agoGLTOGalecto Reports Second Quarter 2025 Operating and Financial ResultsGlobeNewswireBOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and
1y agoGLTOGalecto Reports First Quarter 2025 Operating and Financial ResultsGlobeNewswireBOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and
1y agoGLTOGalecto Reports Full-Year 2024 Financial ResultsGlobeNewswireCompleted strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge
1y agoGLTOGalecto to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that
2y agoGLTOGalecto Reports Third Quarter 2024 Financial ResultsGlobeNewswire- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge
2y agoGLTOGalecto Strengthens Board of Directors with Appointment of Dr. Amy WechslerGlobeNewswireBOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of
2y agoGLTOGalecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge MedicinesGlobeNewswireGalecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic
2y agoGLTOGalecto Announces Reverse Stock SplitGlobeNewswireBOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that it will
2y agoGLTOGalecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with PembrolizumabGlobeNewswireBOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that the first
2y agoGLTOTopline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisGlobeNewswireBOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive topline
3y agoGLTOGalecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 TrialGlobeNewswireBOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today presented a poster with new
3y agoGLTOGalecto Announces Plans to Explore Strategic AlternativesGlobeNewswireBOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has
3y agoGLTOGalecto to Present at Investor Conferences in SeptemberGlobeNewswireBOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer,
3y agoGLTOGalecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewswireBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and
3y agoGLTOGalecto Reports Second Quarter Operating and Financial ResultsGlobeNewswireBOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer,
3y agoGLTOGalecto Set to Join Russell Microcap® IndexGlobeNewswireBOSTON, June 20, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer,
3y agoGLTOGalecto to Present at the Upcoming Jefferies Healthcare ConferenceGlobeNewswireBOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer,
3y agoGLTOGalecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary FibrosisGlobeNewswireBOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer,
3y agoGLTOGalecto to Present Poster at Upcoming ATS 2023 International ConferenceGlobeNewswireBOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer,
3y agoGLTOGalecto Reports First Quarter Operating and Financial ResultsGlobeNewswireBOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and
3y agoGLTOGalecto to Present Two Posters at AACR Annual Meeting 2023GlobeNewswireBOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and
3y agoGLTOGalecto Reports Operating and Financial Results for the Year Ended December 31, 2022GlobeNewswireBOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and
3y agoGLTOGalecto to Participate in Oppenheimer's 33rd Annual Healthcare ConferenceGlobeNewswireBOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and
3y agoGLTOGalecto to Participate in SVB Securities Global Biopharma ConferenceGlobeNewswireBOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and
3y agoGLTOGalecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual MeetingGlobeNewswireIntermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients GB2064 is an oral inhibitor of
4y agoGLTOGalecto Reports Third Quarter Operating and Financial ResultsGlobeNewswireBOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and
4y agoGLTOGalecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis PatientsGlobeNewswireStatistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8,
4y agoGLTOGalecto to Participate in Jefferies London Healthcare ConferenceGlobeNewswireBOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and
4y agoGLTOGalecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022GlobeNewswireLate-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline
4y agoGLTOGalecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer InstituteGlobeNewswireBOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that it has entered
4y agoGLTOGalecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022GlobeNewswireBOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it will host a
4y agoGLTOGB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis TargetGlobeNewswireBOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive results from a planned intermediate assessme
4y agoGLTOGalecto to Participate at H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireBOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating at the upcoming
4y agoGLTOGalecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific JournalGlobeNewswireBOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced a recent publication in the Journal of Cancer Research
4y agoGLTOGalecto Reports Second Quarter Operating and Financial ResultsGlobeNewswireBOSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter en
4y agoGLTOGalecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLCGlobeNewswireBOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that the first patient has been enrolled in the Phase
4y agoGLTOGalecto to Participate at Jefferies Healthcare ConferenceGlobeNewswireBOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will be participating at the upcoming J
4y agoGLTOGalecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual MeetingGlobeNewswireNovel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified Galecto's oral galectin-3 inhibitor candidate, GB1211, reverses galectin-3 induced blockade of checkpoint inhibitors binding to PD-1/PD-L1 in pre-clinical models
4y agoGLTOGalecto to Participate at Upcoming Investor ConferencesGlobeNewswireBOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will present and be available for one-o